Reduced urinary 6β-hydroxycortisol to cortisol ratios in patients with liver cirrhosis

Hepatology Research

Volumn 26, Issue 1, 2003, Pages 28-33

  Shibuya, Masahiko ^a   Echizen, Hirotoshi ^c   Kubo, Suzuko ^a   Tamura, Noboru ^a   Suzuki, Koichi ^a   Ushiama, Hideki ^b   Ohnishi, Akihiro ^b  

^a NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

6 Hydroxycortisol; High performance liquid chromatography; Liver cirrhosis

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; ALBUMIN; AMINOTRANSFERASE; CYTOCHROME P450 3A; FERROUS SULFATE; FUROSEMIDE; GLIBENCLAMIDE; HYDROCORTISONE; LANSOPRAZOLE; RANITIDINE; SPIRONOLACTONE; SUCRALFATE; VITAMIN K GROUP;

ADULT; AGED; ALBUMIN BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; CHRONIC DISEASE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INDUCTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE URINE LEVEL; HUMAN; LIVER CIRRHOSIS; LIVER INJURY; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL; ULTRAVIOLET SPECTROPHOTOMETRY; URINALYSIS;

EID: 0041590962     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(03)00005-6     Document Type: Article

References (24)

1. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-84.
2. Kovacs SJ, Martin DE, Everitt DE, Patterson SD, Jorkasky DK. Urinary excretion of 6β-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations. Clin Pharmacol Ther 1998;63:617-22.
3. Ohnhaus EE, Pak BK. Measurement of urinary 6-β-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur J Clin Pharmacol 1979;28:373-87.
4. Saenger P. 6β-Hydroxycortisol in random urine samples as an indicator of enzyme induction. Clin Pharmacol Ther 1983;34:818-21.
5. Ged C, Rouillon JM, Pichard L, et al. The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 1989;28:373-87.
6. Watkins PB, Turgeon DK, Saenger P, et al. Comparison of urinary 6-β-hydroxycortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 1992;52:265-73.
7. Desager JP, Dumont E, Harvengt C. The urinary 6β-hydroxycortisol excretion in man on inducers and inhibitors of the hepatic mixed function oxidase. Pharmacol Ther 1987;33:197-9.
8. Boulton DW, Arnaud P, DeVane CL. A single dose of methadone inhibits cytochrome P-450 3A activity in healthy volunteers as assessed by the urinary C ratio. Br J Clin Pharmacol 2001;51:350-4.
9. Lillibridge JH, Liang BH, Kerr BM, et al. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 1998;26:609-16.
10. Morita K, Konishi H, Shimakawa H. Fluconazole: a potent inhibitor of cytochrome P-450-dependent drug metabolism in mice and human in vivo. Comparative study with ketoconazole. Chem Pharm Bull 1992;40:1247-51.
11. Ushiama H, Echizen H, Nachi S, Ohnishi A. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in the partial cortisol clearance by 6β-hydroxycortisol formation and plasma lansoprazole levels. Clin Pharmacol Ther 2002;72:33-43.
12. Ng MC, Young RP, Critchley JA, Leung NW, Lau JW, Li AK, Urinary 6β-hyxroxycortisol excretion in Hong Kong Chinese patients with hepatocellular carcinoma and other chronic liver disease. Cancer 1996;77:1427-33.
13. Lee C. 6β-Hydroxycortisol interferes with immunoassay of urinary free cortisol. Clin Chem 1996;42:1290-1.
14. Oka K, Noguchi M, Kitamura T, Shima S. Liquid chromatography and radioimmunoassay compared for determination of cortisol and corticosterone in plasma after dexamethasone suppression test. Clin Chem 1987;33:1639-42.
15. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophageus for bleeding varices. Br J Surg 1973;60:646-9.
16. Bienvenu T, Rey E, Pons G, d'Athis P, Olive G. A simple non-invasive procedure for the investigation of cytochrome P-450 IIIA dependent enzymes in humans. Int J Clin Pharmacol Ther Toxicol 1991;29:441-3.
17. 14C. J Clin Invest 1969;48:344-50.
18. Branch RA, Herbert CM, Read L. Determinants of serum antipyrine half-lives in patients with liver disease. Gut 1973;14:569-73.
19. 14]aminopyrine. Ann Intern Med 1975;83:632-8.
20. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampicin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8.
21. Schuetz EG, Shuetz JD, Grogan WM, et al. Expression of cytochrome P450 3A in amphibian, rat and human kidney. Arch Biochem Biophys 1992;294:206-14.
22. Nakamura J, Yakata M. Age- and sex-related differences in urinary excretion of 6β-hydroxycortisol in humans. Clin Chim Acta 1985;152:193-7.
23. Kinirons MT, O'Shea D, Kim RB, et al. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P450 3A. Clin Pharmacol Ther 1996;66:224-31.
24. Kinirons MT, O'Shea D, Downing TE, et al. Absence of correlations among three putative in vivo probes of human cytochrome P450 3A activity in young healthy men. Clin Pharmacol Ther 1993;54:621-9.